Erdheim-Chester Disease Clinical Trial
Official title:
Subtypes and Prognostic Factors in Erdheim-Chester Disease
Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
| Recruiting |
NCT03329274 -
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
|
||
| Recruiting |
NCT05093335 -
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
|
Early Phase 1 | |
| Completed |
NCT02608619 -
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
|
||
| Terminated |
NCT01727206 -
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
|
Phase 2 | |
| Recruiting |
NCT02089724 -
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
|
N/A | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Recruiting |
NCT05768178 -
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06332183 -
GWAS and EWAS in Patients With Erdheim-Chester Disease
|
||
| Terminated |
NCT04198818 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03794297 -
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
|
Phase 2 | |
| Active, not recruiting |
NCT05092815 -
The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
|
Phase 2 | |
| Recruiting |
NCT04079179 -
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
|
Phase 2 |